Eli Lilly and Boehringer Ingelheim Reveal Results from the P-III (EMPACT-MI) Study of Jardiance to Prevent the Risk of Heart Failure and Death Post Heart Attack
Read More: Eli Lilly & Boehringer Ingelheim
Novartis Reveals the P-IIIb (V-INITIATE) Trial Results of Leqvio for Treating Atherosclerotic Cardiovascular Disease (ASCVD)
Read More: Novartis
BMS Reveals Pooled Interim Results from a Series of P-III (EMERGENT) Studies Evaluating KarXT for Schizophrenia at the SIRS 2024
Read More: BMS
BMS Features the P-I/II Study Results of Krazati in Addition with Cetuximab for the Treatment of Locally Advanced or Metastatic Colorectal Cancer at the AACR 2024
Read More: BMS
Pfizer Reveals the P-III Study Data of Abrysvo for Increased Risk for RSV Disease
Read More: Pfizer
Rapt Therapeutics Highlights Results from the P-II Study of Tivumecirnon in Combination with Keytruda for Treating Head and Neck Cancer
Read More: Rapt Therapeutics
Monopar Therapeutics Commences the P-I Trial of MNPR-101-Zr for Treating Advanced Cancer
Read More: Monopar Therapeutics
Teva Reports the P-III Study Data of Ajovy (fremanezumab) to Prevent Migraine in Chinese Patients
Read More: Teva
Boundless Bio Reports First Patient Dosing with BBI-825 in the P-I/II Study for Cancer Treatment
Read More: Boundless Bio
Enliven Therapeutics Reveals the PoC Results from the P-I Clinical Evaluation of ELVN-001 for the Treatment of Chronic Myeloid Leukemia
Read More: Enliven Therapeutics
AstraZeneca and Daiichi Sankyo’s Enhertu Gains the US FDA’s Accelerated Approval to Treat Metastatic HER2-Positive Solid Tumors
Read More: AstraZeneca & Daiichi
The US FDA Grants FTD to PureTech’s LYT-200 for the Treatment of Head and Neck Cancers
Read More: PureTech
Candel Therapeutics’ CAN-2409 Obtains the US FDA’s Orphan Drug Designation to Treat Pancreatic Cancer
Read More: Candel Therapeutics
Boston Scientific Reports the Commencement of NAVIGATE-PF Study Evaluating Farawave Nav Pulsed Field Ablation Catheter and Faraview Software Module
Read More: Boston Scientific
HeartBeam Highligts Data from the Study of Using Artificial Intelligence for Detecting Arrhythmias
Read More: HeartBeam
Roche’s Ventana HER2 (4B5) Test Gains CE Mark for HER2-Low Metastatic Breast Cancer
Read More: Roche
The US FDA Grants Breakthrough Device Designation to Roche’s Elecsys pTau217 Assay for Diagnosing Alzheimer’s Disease
Read More: Roche
The US FDA Grants Breakthrough Device Designation to Simpson Interventions’ Acolyte Image Guided Crossing and Re-Entry Catheter System
Read More: Simpson
Henlius and Organon Reveal Results from the P-III Study of HLX14, Biosimilar Candidate of Denosumab
Read More: Henlius & Organon
Coherus BioSciences Highlights the Preclinical Data of CHS-1000 for Solid Tumors at the AACR 2024
Read More: Coherus BioSciences
Merus Features the Zenocutuzumab’s Preclinical Results for Cancer Treatment at the AACR 2024
Read More: Merus
Nucleai and GoPath Diagnostics Collaborate on AI-Based Digital Pathology Solutions for Clinical Research and Diagnosis
Read More: Nucleai & GoPath Diagnostics
Transcenta Collaborates with Agilent Technologies on Claudin18.2 Companion Diagnostic to Support the P-III Study of Osemitamab
Read More: Transcenta & Agilent Technologies
Bayer Partners with Google Cloud on AI-Based Solutions for Radiologists
Read More: Bayer & Google Cloud
Merck Animal Health Launches Flocksecure Poultry Health Portal
Read More: Merck Animal Health
NeuroSense and Lonza Join Forces on Exosome-based Biomarkers for the Diagnosis and Treatment of Neurodegenerative Disease
Read More: NeuroSense & Lonzav
Rallybio and Johnson & Johnson Collaborate to Develop Therapies for Preventing Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Read More: Rallybio & Johnson & Johnson
Arvinas and Novartis Join Forces to Develop and Commercialize ARV-766 for Treating Prostate Cancer
Read More: Arvinas & Novartis
Harmony Biosciences and Bioprojet Join Forces to Develop TPM-1116 for Treating Narcolepsy and Other Sleep/Wake Disorders
Read More: Harmony Biosciences & Bioprojet
For an Aggregate of ~$4.9B, Vertex to Acquire Alpine Immune Sciences
Read More: Vertex & Alpine Immune Sciences
Related Post:- PharmaShots Weekly Snapshots (April 01 – April 05, 2024)
